Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: gout

Sodium-Glucose Cotransporter-2 Inhibitors May Decrease Gout Risk in Some Patients

Lara C. Pullen, PhD  |  February 19, 2020

Recent research assessed the risk of gout in patients with type 2 diabetes mellitus prescribed sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with those prescribed a glucagon-like peptide-1 (GLP-1) agonist. The study found patients on the SGLT2 inhibitor had a lower rate of gout, suggesting SGLT2 inhibitors may actually reduce the risk of gout among this patient population…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:GoutSGLT2 inhibitorssodium-glucose cotransporter-2 (SGLT2) inhibitorstype II diabetes

Pegloticase & Methotrexate Combination Therapy May Benefit Patients with Uncontrolled Gout

Michele B. Kaufman, PharmD, BCGP  |  December 11, 2019

Patients with uncontrolled gout may benefit from a combination of pegloticase and methotrexate therapy, according to a small, retrospective study…

Filed under:ConditionsDrug UpdatesGout and Crystalline Arthritis

Potential Link Between OA & Gout

Arthritis & Rheumatology  |  December 2, 2019

Monosodium urate (MSU) crystal formation, deposition and gout flares frequently affect joints that have been damaged or are affected by osteoarthritis. These researchers examined the effects of human cartilage homogenates on MSU crystallization and MSU crystal-induced inflammation…

Filed under:ConditionsGout and Crystalline ArthritisResearch Rheum Tagged with:Arthritis & RheumatologyGoutmonosodium urate crystalsosteoarthritis (OA)Research

Clinical Insights into Gout Management

Staff  |  November 29, 2019

New Draft Gout Guideline Released

Susan Bernstein  |  November 20, 2019

ATLANTA—The authors of the new draft ACR treatment guideline for the management of gout presented the draft guideline on Nov. 13 at the 2019 ACR/ARP Annual Meeting. Based on evidence from more than 130 published studies, there are 42 recommendations, of which 16 were strong, including 27 for urate-lowering therapy (ULT) management, 13 of which…

Filed under:Clinical Criteria/GuidelinesConditionsGout and Crystalline Arthritis Tagged with:2019 ACR/ARP Annual MeetingGout

A CT of the abdomen demonstrated numerous hypodense lesions present in both lobes of the liver, with the largest lesion measuring 2.0 x 3.1 cm.

Case Report: A Patient with Gout Develops Granulomatous Hepatitis

Raj Vachhani, MD, & Angelo L. Gaffo, MD, MSPH  |  November 16, 2019

Case Presentation A 45-year-old man with crystal-proven gout, poorly controlled diabetes and chronic kidney disease was lost to follow-up for six years and presented back to the VA clinic in the midst of a gout flare. He stated he had continued taking 100 mg of allopurinol daily, but his serum urate level was 13.8 mg/dL….

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:Allopurinolgranulomatous hepatitis

Insight into Achieving & Maintaining Target Serum Urate Levels in Gout Patients

Lara C. Pullen, PhD  |  November 11, 2019

A recent study advances the understanding of factors associated with a target serum urate level of 6 mg/dL or less. Researchers found such factors as having a rheumatologist as the main provider of gout care contributed to achieving and maintaining this outcome. However, the presence of co-morbidities lowered a patient’s chances for achieving the target serum urate level, even with allopurinol use…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:AllopurinolGoutserum urate levels

Clinical Insights into Gout Management: Rheumatology Drugs at a Glance Pt. 4

Mary Choy, PharmD, BCGP, FASHP  |  October 14, 2019

Three clinical experts on gout offer their insights into common management errors, clinical pearls, new safety data from the FDA and the role of biologic therapies in the management of gout.

Filed under:Biologics/DMARDsClinical Criteria/GuidelinesConditionsDrug UpdatesGout and Crystalline Arthritis Tagged with:GoutGout Resource Center

Dual-Energy CT May Help Detect Gout Patients at Risk for Heart Disease

Marilynn Larkin  |  September 25, 2019

NEW YORK (Reuters Health)—Dual energy computed tomography (DECT) can differentiate cardiovascular monosodium urate (MSU) deposits from calcium deposits in patients with gout, potentially identifying those at risk of heart disease, researchers say. Sylvia Strobl, MD, of Medical University Innsbruck and colleagues analyzed calcium scores and MSU deposits in 59 patients with gout (mean age: 59;…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:cardiovasculardual energy computed tomographyGoutHeart Diseaseimaging

Obesity, Drinking & Unhealthy Diet Add to Gout Risk

Lisa Rapaport  |  September 25, 2019

(Reuters Health)—Behavior changes could potentially reduce a large part of the risk for developing gout, a U.S. study suggests. Based on data from more than 14,000 people, researchers calculated how much factors like being overweight, following a diet that isn’t heart healthy, drinking alcohol or taking diuretics contribute to high levels of uric acid—a precursor…

Filed under:ConditionsGout and Crystalline ArthritisResearch Rheum Tagged with:AlcoholArthritis & RheumatologyGoutlifestyleObesityRisk Factors

  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 59
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences